{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:15:58Z","timestamp":1791389758976,"version":"4.3.3"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stichting VU medisch centrum Fonds","award":["399"],"award-info":[{"award-number":["399"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Remyelination failure hampers symptomatic recovery in multiple sclerosis (MS), underlining the importance of developing remyelinating therapies. Optic neuritis is currently the most established method of measuring remyelination in MS trials. Complementary more generalisable methods of measuring remyelination are required to confirm treatment efficacy. Measuring internuclear ophthalmoplegia (INO) with infrared oculography provides such a method. Moreover, this method can be expanded with a test for selecting likely treatment responders by using fampridine. The aim of this trial is to investigate the (long-term) remyelinating effects of clemastine fumarate in patients with MS and INO and to evaluate if treatment response can be predicted using fampridine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>RESTORE is a single-centre double-blind randomised placebo-controlled trial of clemastine fumarate versus placebo. Prior to clemastine treatment improvement in oculographic features of INO after a single 10\u2009mg dose of fampridine is measured in all participants and used to predict the treatment response to clemastine. Eighty individuals with MS and INO will be 1:1 randomised to 4\u2009mg of clemastine fumarate two times a day for 6 months or equivalent placebo. Our primary outcome is improvement in the Versional Dysconjugacy Index-area under the curve, measured by infrared oculography after 6 months of treatment. Participants are assessed for persistent treatment effects 6, 18 and 30 months after end of treatment. Secondary outcome measures include other oculography parameters including double-step saccades, retinal imaging, visual acuities, physical disability, cognition and patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Clemastine is a registered and very well-established drug with well-known safety and side effects. The protocol was approved by the medical ethical committee of the Amsterdam UMC, location VUMC and the Dutch Central Committee on Research Involving Human Subject. Written informed consent is obtained from all participants. The results will be published in peer-reviewed medical scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      EudraCT: 2021-003677-66, ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05338450\">NCT05338450<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-076651","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T01:11:11Z","timestamp":1706663471000},"page":"e076651","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE)"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05338450","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0453-6449","authenticated-orcid":false,"given":"Sam","family":"Hof","sequence":"first","affiliation":[{"name":"MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentius J","family":"van Rijn","sequence":"additional","affiliation":[{"name":"Ophthalmology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"},{"name":"Opthalmology, Onze Lieve Vrouwe Hospital, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M J","family":"Uitdehaag","sequence":"additional","affiliation":[{"name":"MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny A","family":"Nij Bijvank","sequence":"additional","affiliation":[{"name":"MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"},{"name":"Ophthalmology, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Petzold","sequence":"additional","affiliation":[{"name":"MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, The Netherlands"},{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2025121513102680000_14.1.e076651.1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025121513102680000_14.1.e076651.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32346-2"},{"key":"2025121513102680000_14.1.e076651.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00200-9"},{"key":"2025121513102680000_14.1.e076651.4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10633-022-09896-6","article-title":"Pattern ERGs suggest a possible retinal contribution to the visual acuity loss in acute optic neuritis","volume":"145","author":"Kleerekooper","year":"2022","journal-title":"Doc Ophthalmol"},{"key":"2025121513102680000_14.1.e076651.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac207"},{"key":"2025121513102680000_14.1.e076651.6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217635120","article-title":"MWF of the corpus callosum is a robust measure of remyelination: results from the ReBUILD trial","volume":"120","author":"Caverzasi","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025121513102680000_14.1.e076651.7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/brain\/awac334","article-title":"Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration","volume":"146","author":"Tonietto","year":"2023","journal-title":"Brain"},{"key":"2025121513102680000_14.1.e076651.8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/brain\/awac436","article-title":"Quantitative myelin imaging with MRI and PET: an overview of techniques and their validation status","volume":"146","author":"van der Weijden","year":"2023","journal-title":"Brain"},{"key":"2025121513102680000_14.1.e076651.9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol"},{"key":"2025121513102680000_14.1.e076651.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.1.51"},{"key":"2025121513102680000_14.1.e076651.11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000085863.54218.72","article-title":"Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography","volume":"61","author":"Frohman","year":"2003","journal-title":"Neurology"},{"key":"2025121513102680000_14.1.e076651.12","doi-asserted-by":"crossref","first-page":"e2299","DOI":"10.1212\/WNL.0000000000007499","article-title":"Diagnosing and quantifying a common deficit in multiple sclerosis","volume":"92","author":"Nij Bijvank","year":"2019","journal-title":"Neurology"},{"key":"2025121513102680000_14.1.e076651.13","doi-asserted-by":"crossref","first-page":"103824","DOI":"10.1016\/j.msard.2022.103824","article-title":"The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis","volume":"63","author":"Hof","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025121513102680000_14.1.e076651.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200695","article-title":"A standardized protocol for quantification of saccadic eye movements: DEMoNS","volume":"13","author":"Nij Bijvank","year":"2018","journal-title":"PLoS One"},{"key":"2025121513102680000_14.1.e076651.15","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/brain\/awac474","article-title":"A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage","volume":"146","author":"Nij Bijvank","year":"2023","journal-title":"Brain"},{"key":"2025121513102680000_14.1.e076651.16","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000291009.69226.4d"},{"key":"2025121513102680000_14.1.e076651.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.98"},{"key":"2025121513102680000_14.1.e076651.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.108"},{"key":"2025121513102680000_14.1.e076651.19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/cns.13096","article-title":"Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: a randomized double-blind, placebo-controlled cross-over trial","volume":"25","author":"Kanhai","year":"2019","journal-title":"CNS Neurosci Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-076651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:10:34Z","timestamp":1765833034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-076651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjopen-2023-076651"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-076651","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}